Adverse drug reactions (ADR) were originally defined as unintended responses to drugs that occur at doses used in treatment or prevention of disease. In some jurisdictions this has now been extended to include medication errors and unauthorized use of drugs such as drug abuse and misuse. For almost four decades a widely accepted classification has divided ADRs into Type A reactions that are the result of augmented effects of the usual pharmacological action of the drug and therefore thought to be dose related, predictable and preventable reactions, and Type B "Bizarre or idiosyncratic" ADRs that are exemplified by reactions which are less dependent on drug dose and unpredictable based on the pharmacological action of the drug [1] . The paradigm shift over the last 10 years has been recognition that predisposition to Type A reactions is dependent both on dose and genetic factors and that the less prevalent Type B reactions which include immunologically-mediated reactions can be both dose-related and predictable based on a defined effect outside of their primary pharmacological action (Figure 1 ). Hence as we increasingly move into the complex therapeutic arena of using small and large molecule drugs with complex on and off target effects, more contemporary classifications of ADRs which do not distinguish drug reactions based on their dose dependency, predictability or genetic basis are becoming more relevant and useful ( Figure 1) .
In thinking about dose dependency and laws of mass action not all immunologically mediated reactions are created equally. Although a certain threshold of exposure is required to prime an individual to both B-cell (IgE mediated) and T-cell mediated drug reactions the kinetics and dose responsiveness of these reactions is distinct. In the most extreme case of anaphylaxis, for instance the immune system has been primed to recognize extremely small amounts of antigen which are highly effectively This article is protected by copyright. All rights reserved. The dose-dependency of T-cell mediated reactions is evident both in vivo and in vitro.
More recently this has been elegantly demonstrated with drugs like abacavir which causes a drug hypersensitivity reaction that is CD8+T cell dependent and restricted by the class I MHC allele, HLA-B*57:01. In the clinic we saw the intensity of hypersensitivity symptoms increase after abacavir dosing with rapid offset of symptoms following abacavir discontinuation. This concentration effect was further reproduced in vivo with dose responsiveness seen on abacavir patch testing and ex vivo in ELISpot assays [3, 4] . It is now known that the specific mechanism by which abacavir causes hypersensitivity is through concentration dependent, non-covalent interactions with HLA-B*57:01 [5] [6] [7] . This interaction of abacavir with HLA-B*57:01 alters the repertoire of self-peptides bound and recognized by T-cells [5] [6] [7] .
The crystal structure of abacavir bound to peptide and HLA-B*57:01 has now been This article is protected by copyright. All rights reserved.
solved [5] [6] [7] . The occurrence and severity of other HLA-restricted, T-cell mediated reactions such as allopurinol associated Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) is related to accumulation of the long-acting metabolite, oxypurinol which occurs in the setting of renal failure [8] . More recent examples of phenytoin SJS/TEN/DRESS and nevirapine DRESS suggest that genetic variation in specific CYP enzymes leading to delayed clearance of the parent drug predispose to these reactions [9, 10] . For example, in the case of phenytoin the occurrence and severity of SJS/TEN/DRESS in Asian populations was associated with both CYP2C9*3 and phenytoin levels [9] . This article is protected by copyright. All rights reserved.
Drugs thus have on-target effects that are related to their primary pharmacological mode of action as well as off-target effects and the effect of drug dose and drug exposure is important for each of these. In addition, as we are now able to characterize the pathogenesis of many off-target ADRs the term "idiosyncractic" has become erroneous. In cases where the pathogenesis of the ADR is as yet unknown marked intensification of an ADR on second exposure to the drug suggests immunological memory (Figure 1) . It is now possible to predict many serious offtarget ADRs by modeling drug-receptor interactions and in the case of immunologically-mediated reactions by identifying the immunopathogenesis of these reactions and their immunogenetic basis [12] . Success stories in prediction that have been translated into routine clinical practice to prevent morbidity and mortality from ADRs include HLA-B*57:01 screening to prevent abacavir hypersensitivity and HLA-B*15:02 screening in Southeast Asians to prevent carbamazepine SJS/TEN [13, 14] . In addition to advances in the prediction and prevention of off-target adverse drug effects, identification of these "off target effects" is also now also being used in positive ways to repurpose old drugs for new indications. 
